Recent News

• 03.20.2026 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 02.26.2026 - Iovance Biotherapeutics to Present at Upcoming Conferences
• 02.24.2026 - Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
• 02.24.2026 - Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

Recent Filings

• 03.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.06.2026 - 4 Statement of changes in beneficial ownership of securities